Spravato nasal spray, also known as esketamine, can now be used to treat depression in adults with treatment-resistant depression. $3,500 iPhone possible? What to know 📋 How to talk money 🤑 ...

TITUSVILLE, N.J., Sept. 9, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive results from tw ...

Each Spravato nasal spray device delivers 2 sprays containing a total of 28mg of esketamine; the product is classified as a Schedule III controlled substance.

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...

That’s where Spravato comes in. It’s a nasal spray with a key ingredient called esketamine, which is related to the anesthetic ketamine. What makes it different is how it works ...

A New Antidepressant with a Novel Mechanism of Action to Treat Major Depressive Disorder in AdultsTORONTO, July 22, 2020 /CNW/ - The Janssen Pharm ...

The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is ...

The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and other ...

On Tuesday, the U.S. Food and Drug Administration approved Spravato (esketamine) nasal spray, a new antidepressant drug by Janssen Pharmaceuticals. The fast-acting drug, chemically related to the ...

I was a participant in a Phase 3 clinical trial for esketamine, which came to market as the nasal spray Spravato. The Food and Drug Administration approved it for treatment-resistant major depression.

Spravato nasal spray is offered at Dakota Adult and Pediatric Psychiatry in Fargo. Anne Sara Bien-Aime / WDAY News. By Anne Sara Bien-Aime. March 01, 2024 at 11:00 PM. Comments Share ...